Last updated on April 20, 2014 at 17:20 EDT

Latest Newcastle Innovation Limited Stories

2013-02-20 08:28:16

REHOVOT, Israel and NEWCASTLE, Australia, February 20, 2013 /PRNewswire/ -- Leading drug developer Proteologics Ltd. (TASE:PRTL) and Newcastle Innovation Limited, the technology transfer company of the University of Newcastle, Australia, have entered into an exclusive license agreement to develop and commercialize therapeutics for respiratory and other diseases based on the novel target Midline-1, an E3 ubiquitin ligase. University of Newcastle researchers* identified...